Cited by 22

Genotyping Is a Valuable Diagnostic Complement to Neonatal Screening for Congenital Adrenal Hyperplasia due to Steroid 21-Hydroxylase Deficiency1

Nordenström, Anna, Thilén, Astrid, Hagenfeldt, Lars, Larsson, Agne, Wedell, Anna·1999·The Journal of Clinical Endocrinology & Metabolism

Abstract

To evaluate genotyping as a diagnostic complement to neonatal screening for congenital adrenal hyperplasia, 91 children who had been diagnosed with this condition between 1986 and 1997 were analyzed for mutations in the steroid 21-hydroxylase gene. Screening levels of 17-hydroxyprogesterone were compared in patients representing different genotypes. Genotyping was performed using allele-specific PCR, the patients were divided into four groups according to the severity of their mutations, and screening results were compared between these groups as well as with 141 values representing false positive samples. The screening levels of 17-hydroxyprogesterone were significantly different in the five groups of samples. Values above 500 nmol/L were clearly associated with the most severe genotypes, whereas conclusions concerning disease severity could not be drawn from individual samples representing lower levels. For example, values around 150-200 nmol/L could be seen in children with all degrees of disease severity and could also constitute false positive samples. We conclude that genotyping is a valuable diagnostic tool and a good complement to neonatal screening, especially in confirming or discarding the diagnosis in cases with slightly elevated 17-hydroxyprogesterone levels. An additional benefit is that it provides information on disease severity, which reduces the risk of overtreatment of mildly affected children.

Integrity signals

Registry

Crossref · 10.1210/jcem.84.5.5651

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Several studies of genotyping of samples from screening programs have suggested that this is a potentially useful adjunct to hormonal measurements, but there has been no large-scale study of its efficacy as a second-tier screen in actual use.

    “Several studies of genotyping of samples from screening programs have suggested that this is a potentially useful adjunct to hormonal measurements (277-282), but there has been no large-scale study of its efficacy as a second-tier screen in actual use.”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Nordenström, A., Thilén, A., Hagenfeldt, L., Larsson, A., & Wedell, A.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
1999-05
Volume
84
Issue
5
Pages
1505-1509
ISSN
  • 0021-972X
  • 1945-7197
Cited by
2
References
8
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review